Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Aim: A small proportion of chronic hepatitis B patients have persistently detectable serum hepatitis B virus (HBV) DNA despite lamivudine therapy. The incidence and clinical outcomes of patients who persistently have detectable serum HBV-DNA during lamivudine therapy was investigated. Method: We enrolled 221 chronic hepatitis B patients who underwent lamivudine therapy for more than 6 months. Among them, 180 were HBeAg positive. Serum HBV-DNA, HBeAg, anti-HBe and alanine aminotransferase (ALT) levels were serially monitored. The study groups were defined, using a hybridization assay, as patients with reductions in serum HBV-DNA below the detectable level (group I) or patients with persistently detectable serum HBV-DNA (group II) during the initial 6 months of lamivudine therapy. Results: The incidence of patients who had persistently detectable HBV-DNA was 7.7%. After the first year, the rates of viral breakthrough, HBeAg loss and serum ALT normalization of group I versus group II were 21% versus 63%, 38% versus 0%, and 71% versus 28%, respectively (P < 0.001). The log10 reduction of serum HBV-DNA at 6 months was -4.58 log10 for group I and -1.97 log10 for group II (P < 0.001, bDNA assay). There were no pretreatment lamivudine-resistant mutants in group II. Conclusion: Lamivudine had little effect on serum HBV-DNA suppression, viral breakthrough suppression and rate of HBeAg loss and ALT normalization in chronic hepatitis B patients with persistently detectable serum HBV-DNA during the initial 6 months of therapy. Early termination of lamivudine therapy is advocated for these patients.

Original languageEnglish
Pages (from-to)1220-1225
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume22
Issue number8
DOIs
Publication statusPublished - 2007 Jan 1

Keywords

  • Chronic hepatitis B
  • Hepatitis B virus DNA
  • Lamivudine

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy'. Together they form a unique fingerprint.

  • Cite this